Legal & General Group Plc Has $2.75 Million Stock Position in Bausch Health Companies Inc. (NYSE:BHC)

Legal & General Group Plc reduced its stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 339,821 shares of the company's stock after selling 50,161 shares during the period. Legal & General Group Plc owned 0.09% of Bausch Health Companies worth $2,746,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BHC. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Bausch Health Companies by 46.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock valued at $38,501,000 after acquiring an additional 1,510,445 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock worth $26,614,000 after buying an additional 1,263,706 shares in the last quarter. O Shaughnessy Asset Management LLC boosted its holdings in Bausch Health Companies by 989.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 611,890 shares of the company's stock worth $4,940,000 after buying an additional 555,709 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in shares of Bausch Health Companies in the 4th quarter valued at approximately $1,594,000. Finally, Trexquant Investment LP lifted its position in shares of Bausch Health Companies by 155.4% in the 4th quarter. Trexquant Investment LP now owns 298,334 shares of the company's stock valued at $2,405,000 after acquiring an additional 181,532 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. StockNews.com downgraded shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Wednesday, April 23rd. Royal Bank of Canada cut their target price on shares of Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating for the company in a research report on Monday, April 7th. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company's stock. According to MarketBeat.com, Bausch Health Companies presently has a consensus rating of "Hold" and an average target price of $7.17.

Bausch Health Companies Stock Performance

Shares of BHC traded up $0.01 during trading hours on Tuesday, reaching $5.42. 129,502 shares of the company traded hands, compared to its average volume of 2,693,480. The stock's fifty day moving average is $6.21 and its 200 day moving average is $7.29. The stock has a market cap of $2.00 billion, a P/E ratio of -45.20, a price-to-earnings-growth ratio of 0.37 and a beta of 0.43. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. On average, equities research analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.